Strategy for chronic rejection in recipient of living-related liver transplantation.
Koyamada
N
N
2nd Department of Surgery, Tohoku University School of Medicine, Sendai, Japan. chibikun@ea.mbn.or.jp
Ohkohchi
N
N
Doi
H
H
Orii
T
T
Kikuchi
H
H
Chubachi
S
S
Sekiguchi
S
S
Kawagishi
N
N
Haga
I
I
Nakajima
N
N
Satomi
S
S
Oguma
S
S
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002675:Child, Preschool; D002908:Chronic Disease; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005190:Family; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology* / Q000502:physiology; D019520:Living Donors; D008214:Lymphocytes / Q000276:immunology / Q000473:pathology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D012086:Reoperation; D016559:Tacrolimus / Q000627:therapeutic use
D006146:Guanidines; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C037258:gusperimus; D016559:Tacrolimus; D008775:Methylprednisolone